Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age Subgroup
10.1080/10428194.2017.1298755
Saved in:
Main Authors: | Heinz Ludwig, Meletios A. Dimopoulos, Philippe Moreau, Wee Joo Chng, Hartmut Goldschmidt, Roman Hajek, Thierry Facon, Ludek Pour, Ruben Niesvizky, Albert Oriol, Laura Rosinol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Antonio Palumbo, Heidi Gillenwater, Nehal Mohamed, Sanjay Aggarwal, Shibao Feng, Douglas Joshua |
---|---|
Other Authors: | MEDICINE |
Format: | Others |
Published: |
Taylor & Francis
2018
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/141100 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
by: Chng, W-J, et al.
Published: (2022) -
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
by: Moreau, P, et al.
Published: (2022) -
Carfilzomib-Dexamethasone vs Subcutaneous or Intravenous Bortezomib in Relapsed or Refractory Multiple Myeloma: Secondary Analysis of Phase 3 ENDEAVOR Study
by: Hartmut Goldschmidt, et al.
Published: (2018) -
A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1)
by: Chen, Yunxin, et al.
Published: (2021) -
Dexamethasone in Cerebral Malaria
by: Anthony Hall, et al.
Published: (2018)